There is a particular kind of confidence that comes from having spent decades inside the machinery of an industry rather than observing it from a distance. Marek Wasiluk, founder and CEO of CLINMARK, carries that confidence quietly. He does not speak about clinical research the way an outsider might, in sweeping statements about innovation and disruption. He speaks about it the way someone speaks about a craft they have practiced for more than twenty five years, with precision, patience, and a clear sense of what actually works when a study leaves the page and enters the real world.
That distinction, between what looks good in theory and what functions in practice, sits at the center of almost everything Marek has built. It shaped his early years in clinical operations, it shaped the growth of CLINMARK since 2001, and it continues to shape the way he thinks about leadership, technology, and the future of an industry that is expanding into new markets faster than ever before.
To understand why Marek has earned a place among the leaders advancing thoughtful, science driven progress in 2026, it helps to trace the arc of a career that began with hands on operational work and grew into something far larger: a philosophy of leadership built on humility, adaptability, and an unwavering belief that complexity should never be mistaken for quality.
It is also worth understanding what that philosophy looks like when it is tested against reality, because clinical research offers few places to hide. Protocols fail in ways no one predicted. Regulatory expectations shift mid programme. Patients, sites, and sponsors all bring their own constraints to a process that is supposed to move in a straight line but rarely does. Marek treats this as the normal condition of the work, something to plan for rather than something to be caught off guard by.
From the Field to the Front Office
Marek did not enter clinical research chasing prestige or a title. He was drawn to something more fundamental: the intersection of medicine, science, human impact, and problem solving. It is a combination that continues to animate him today, more than two decades later.
“Clinical research requires translating scientific ideas into practical solutions that can ultimately reach patients. I found this combination extremely motivating,” he says, describing what first pulled him into the field.
His early years were spent in operational roles, the kind of work that involves sites, investigators, and the unglamorous realities of running a trial. He moved through management and eventually into executive leadership, but he never treated that progression as a departure from the ground floor of the industry. If anything, it became the foundation for everything that followed.
Those years taught him a lesson that many executives learn too late, if they learn it at all: a study can look flawless on paper and still encounter serious difficulty once it reaches the people responsible for delivering it. Recruitment stalls. Timelines slip. Sites face constraints that no protocol fully anticipates. Marek absorbed these realities early, and they never left him.
Since founding CLINMARK in 2001, he has treated the company as both a professional achievement and a continuous education in leadership. Building an organization over more than twenty years, he explains, is not simply about setting a strategic direction. It requires assembling the right teams, giving them genuine ownership, and ensuring the organization can adapt as the industry around it keeps changing.
“My journey has taught me that leadership in clinical research is not about becoming distant from operations. It is about understanding the entire ecosystem and helping people make complex things simpler, clearer, and more achievable,” he reflects.
Even now, with responsibilities that look nothing like those of his early career, Marek insists he has never lost the operational instincts that shaped him. Before making a strategic decision, he still asks how it will land on the people who have to execute it. That habit, more than any single credential or milestone, may be the clearest thread running through his career.
It is a habit that many executives lose over time, often without noticing. As responsibilities grow and calendars fill with strategy meetings rather than site visits, the operational texture of the work can start to feel abstract. Marek has made a deliberate effort to resist that drift, continuing to think in terms of the people affected by a decision before he thinks about how that decision will read in a strategy document.
A Philosophy Built on Simplicity
Ask Marek what broad experience across the clinical research spectrum has taught him, and he does not talk about mastery. He talks about perspective.
Having worked across clinical operations, monitoring, and executive strategy, he has learned to examine problems from multiple angles simultaneously, because decisions made at the top rarely stay contained at the top. A single executive choice can ripple down to a CRA’s daily workload, a site’s ability to enroll patients, the integrity of the data, or the experience of a patient participating in a trial.
“I always ask: How will this work operationally? What are the risks? Does it create unnecessary complexity? And, most importantly, does it bring real value?” he says of his decision making process.
This is where Marek’s thinking becomes most distinctive. In an industry that often equates sophistication with complexity, he takes the opposite view. Experience, he argues, helps leaders separate theoretical concerns from genuine operational challenges. Not every problem demands a sweeping transformation. Sometimes the most effective solution is to remove a process rather than add one.
“In clinical research, complexity is sometimes necessary, but unnecessary complexity should never be accepted as a sign of sophistication,” he says, a principle that has quietly guided much of his leadership approach.
That principle extends into what Marek considers the essential qualities of effective leadership in a field as demanding as clinical research. Intellectual curiosity comes first, because the industry never stops evolving and leaders who stop learning quickly fall behind. Adaptability follows closely, since no single model works across every country, therapeutic area, or development program. Leaders, he says, must know when to standardize and when to adjust.
Decisiveness matters just as much. Clinical research generates enormous volumes of information and involves a wide range of stakeholders, and waiting for perfect information is rarely realistic. A leader has to weigh the available evidence, understand the risk, and move forward.
Underlying all of it, though, is something Marek treats as non negotiable: ethics and responsibility. The industry exists to serve human health, and commercial pressure, in his view, can never be allowed to outweigh scientific integrity, patient safety, or quality.
“For me, effective leadership means combining knowledge with humility. No individual can know everything. The role of a leader is therefore not to pretend to have all the answers, but to build strong teams and create an environment where expertise can be used effectively,” he explains.
Taken together, these qualities describe a leadership style that is less about personal authority and more about creating the conditions for good decisions to happen throughout an organization. Marek does not present himself as the person with every answer. He presents himself as someone responsible for making sure the right answers can surface from wherever they happen to live, whether that is a monitor working directly with a site or a scientist reviewing a complex dataset.
Lessons From a Global Stage
Few executives can speak with authority across as many regions as Marek. His work has taken him through Europe, Africa, the Middle East, Asia, and other international markets, and the experience has left him with a conviction that shapes nearly every strategic conversation he has today: global does not mean identical.
Each region carries its own regulatory framework, healthcare infrastructure, cultural context, and approach to research. A strategy that performs flawlessly in one country can fall flat in another. This becomes especially important, he notes, when working in emerging markets, which are too often viewed simply as additional recruitment territory.
“I believe this is far too simplistic. Successful clinical research requires understanding the local healthcare ecosystem, building relationships and recognizing both the opportunities and the limitations of the environment,” Marek says.
His solution is not to choose between global consistency and local flexibility, but to combine them. Sponsors need uniform standards, quality, and compliance across their programs. At the same time, implementation has to reflect local realities, whether that means navigating a distinct regulatory pathway, understanding site capabilities, managing patient expectations, or solving logistical challenges specific to a region.
“The key is to combine global standards with local intelligence,” he says,
It is a line that distills years of international experience into a single guiding idea. Marek is equally clear that local expertise should never be underestimated. The strongest global strategies, in his experience, are the ones built when international know-how and local knowledge work together rather than in isolation.
This is not a lesson Marek learned from a single project. It emerged gradually, across years of watching sponsors underestimate regions they did not fully understand, and years of watching what happens when that mistake is avoided instead. A market that appears secondary on paper can hold considerable scientific expertise and a highly capable investigator community. A market that looks straightforward can conceal regulatory nuances that only surface once a study is already underway. The difference, in Marek’s experience, almost always comes down to whether an organization did the work of understanding a region before committing to it.
This global perspective has also shaped how Marek thinks about resilience, particularly in moments when a project is already under strain. Delayed recruitment, unrealistic timelines, struggling sites, and decisions made earlier that create complications later are familiar territory for anyone who has spent decades managing international trials.
“Resilience is not about simply working harder when a problem appears. It is about creating systems and teams that can recognize risks early and respond quickly,” he explains.
Transparency, he adds, has proven essential. Problems rarely disappear because an organization avoids discussing them. The earlier a risk surfaces and gets communicated, the better the chances of finding a workable solution. This belief has shaped how Marek builds teams, favoring people who are equipped to take responsibility and make decisions rather than organizations where every issue has to move through layer after layer of approval.
“Speed is important, but speed without control can create additional risks. The objective should therefore be controlled agility: the ability to respond quickly while maintaining quality and oversight,” he says, offering a phrase that captures much of his operating philosophy in a single line.
Controlled agility, as Marek describes it, is a working principle built from years of watching what happens at both extremes: organizations that move so cautiously they lose valuable time, and organizations that move so quickly they lose control of quality. He has positioned CLINMARK deliberately between the two, favoring teams that can act without waiting for permission at every step, but only within a structure that keeps oversight intact.
Technology With a Purpose
Digitalization has transformed clinical trials over the past decade, introducing new systems, remote methodologies, and vast amounts of data. Marek is not opposed to any of it. What he resists is the assumption that digital automatically means better.
“Digitalization genuinely adds value when it solves a real problem,” he says plainly.
Technology, in his assessment, earns its place when it improves data access, strengthens oversight, reduces repetitive manual work, or genuinely improves the experience for patients through remote and digital approaches. What concerns him is the tendency within the industry to introduce new tools simply because they exist, layering on additional systems, interfaces, and training requirements without delivering a meaningful improvement.
His test for any new technology is deliberately simple. Before adopting something new, organizations should ask what specific problem it solves. If the answer is unclear, he suggests, the technology probably is not necessary.
“The best digital solutions are often the ones that people barely notice because they simplify the process rather than making it more complicated,” he says. Technology, in his view, should support the people doing the work rather than create more of it for them.
This same discipline extends to how Marek evaluates innovation more broadly. Rather than asking whether a new solution looks impressive, he asks what happens if an organization chooses not to use it. If there is no clear answer, caution is warranted. Clinical research, he points out, unfolds in a real operational environment where sites have limited time, patients bring varying levels of digital literacy, and study teams are already juggling multiple systems.
“Innovation is important, but responsible innovation is more important. The goal should not be to have the most technologically advanced study. The goal should be to have the most effective study,” he says, a distinction he returns to often.
Artificial intelligence receives the same measured enthusiasm. Marek sees genuine potential in AI and automation, particularly for repetitive tasks, large datasets, and pattern recognition. AI, he believes, can support data review, risk identification, feasibility assessments, and the analysis of complex information, freeing experienced professionals to focus on work that requires judgment.
But he is quick to push back against the idea that AI will simply replace clinical research professionals. Data signals can look unusual for many different reasons, and understanding whether something represents a genuine risk still requires scientific, medical, and operational judgment that only experienced people can provide.
“For me, the most promising future is not AI instead of people, but AI supporting people,” he says. “AI has enormous potential, but enthusiasm must always be accompanied by critical thinking.”
This balance between openness and skepticism is characteristic of how Marek approaches almost every emerging tool in the industry. He is not interested in resisting change for its own sake, and he has watched enough of the industry’s evolution to know that standing still is not a viable strategy. But he is equally unwilling to adopt something simply because it carries the label of innovation. In a highly regulated environment where accountability has to be traceable, he believes organizations owe it to their patients and sponsors to understand exactly how a decision was reached, whether a human or a machine reached it first.
Quality Without Bureaucracy
If there is one misconception Marek is eager to correct, it is the idea that quality and agility sit in opposition to one another. In his experience, the opposite is true. Well designed quality systems, he argues, actually make organizations more agile, because people understand their responsibilities, the risks involved, and the frameworks guiding their decisions.
“I do not believe quality and agility are opposites,” he says directly.
The real danger, in his view, appears when quality becomes synonymous with bureaucracy. More documents do not automatically produce better quality. More layers of approval do not automatically produce better decisions. A strong quality system, he believes, focuses attention on what genuinely matters rather than accumulating processes for its own sake.
“For me, quality means being able to demonstrate that we did the right thing, for the right reason, at the right level of control,” he explains.
This risk based thinking extends to how Marek approaches innovation within a regulated environment. New approaches should not be dismissed simply because they are new, but they need to be introduced responsibly, with appropriate oversight built in from the start. When quality systems are practical and grounded in real risk rather than reflexive caution, he says, they end up supporting innovation instead of blocking it.
That same strategic patience shapes his view of emerging markets, which he sees as far more than additional recruitment capacity. Many regions, he notes, are advancing rapidly in healthcare infrastructure, scientific expertise, regulatory maturity, and access to innovative therapies, creating real opportunities for global clinical development.
“Countries that continue to invest in clinical research infrastructure, regulatory efficiency and professional development will become increasingly important contributors to global development programmes,” he says, pointing to a future where the geography of clinical research looks meaningfully different from today.
He is careful to add that entering these markets requires strategy, not just ambition. A sponsor that moves into a new country without understanding its regulatory environment, site landscape, and patient population takes on unnecessary risk. The opportunity, as he sees it, lies in building long term capabilities and partnerships rather than short term recruitment pushes.
There is also a broader scientific argument behind his interest in expanding participation across regions. Treatments do not always behave identically across different populations and healthcare systems, and Marek believes that broader geographical representation in clinical research ultimately strengthens the evidence base that sponsors, regulators, and patients rely on. The future of the industry, in his view, will be shaped as much by where research happens as by how it is designed.
Building CLINMARK’s Next Chapter
For readers encountering CLINMARK for the first time, Marek describes the organization in refreshingly grounded terms. CLINMARK is a clinical research and consulting company that helps organizations translate development plans into practical execution. Its work spans the full clinical research ecosystem, including clinical operations, project management, monitoring, data and safety management, regulatory and medical consulting, quality oversight, audits, and specialized consulting services.
What distinguishes the company, according to Marek, is the combination of operational experience and consulting expertise. CLINMARK does not simply advise clients on what should happen. It understands what it actually takes to implement a strategy inside real clinical environments, a distinction built from more than two decades of supporting hundreds of trials and consulting projects across numerous countries.
“Ultimately, we want to be a partner that clients can involve not only when everything is going according to plan, but particularly when they face complex challenges and need an experienced team to find a solution,” he says.
Much of CLINMARK’s success in managing complex international programs, Marek explains, comes down to avoiding rigid models. Every country introduces its own variables, from regulatory requirements to site capabilities to cultural factors, so the company begins each project by understanding its specific objectives and risks before combining standardized quality principles with local expertise and tailored solutions. Clear communication and direct access to experienced decision makers round out the approach, alongside a workforce that Marek considers the true engine of the business.
“Clinical research is ultimately a people driven industry. Systems and processes are important, but experienced professionals are the ones who identify risks, build relationships and make difficult decisions,” he says.
Looking ahead, Marek is focused on several priorities as CLINMARK enters its next stage of growth. One is the deeper integration of clinical operations, regulatory strategy, and quality oversight, functions that still operate in silos at many organizations. He believes earlier integration helps identify risks before they escalate into major operational problems. CLINMARK is also expanding its capabilities in advanced therapies, medical devices, complex global projects, and technology supported clinical operations, alongside a measured approach to international expansion.
“For us, expansion does not simply mean entering more markets. It means developing meaningful capabilities and partnerships in regions where we can provide real value to clients,” he says.
He sees a particular opportunity in supporting biotech and smaller pharmaceutical companies that want to expand globally but lack extensive infrastructure of their own. These organizations need partners capable of offering both strategic guidance and practical execution, a combination Marek believes will only grow more valuable as the industry becomes more complex.
That belief shapes how CLINMARK positions itself in a market crowded with providers of every size. Rather than competing purely on scale, the company leans on a combination of strategic thinking and hands on delivery that Marek sees as increasingly rare. Sponsors, particularly smaller ones navigating unfamiliar regions for the first time, are not simply looking for a vendor to execute tasks. They are looking for a partner who can help them think through a programme from the earliest planning stages through to the final report, and who can be trusted to raise a concern honestly rather than simply agreeing with whatever direction a client has already chosen.
A Vision Rooted in Values
When Marek describes his vision for CLINMARK’s future, he does not talk about scale for its own sake. He talks about identity.
“My vision is for CLINMARK to continue growing as an internationally recognized organization that combines scientific understanding, operational excellence and practical problem solving, while staying true to the values that have shaped the company from the beginning,” he says.
Those values are captured in what Marek calls the company’s 5×E framework: Expertise, Excellence, Engagement, Efficiency, and aEsthetics. He is careful to note that these are not slogans chosen to decorate a website. They describe how the company works, how its people are expected to grow, and the experience clients and partners should have every time they work with CLINMARK.
“Our 5×E values are not simply words we use to describe the organization. They represent the way we want to work, the way we want our people to develop and, ultimately, the experience we want our clients and partners to have when working with CLINMARK,” he explains.
Growth remains important to him, but never at the expense of quality, responsibility, or the values that built the company. As CLINMARK expands internationally, Marek wants it to remain the kind of organization clients turn to specifically because projects are complex, because conventional solutions fall short, and because they need experienced people willing to take responsibility and find practical answers.
At the same time, he wants the organization to stay curious and open to change, aware that the clinical research industry will look markedly different in the years ahead as technology evolves, new markets rise in importance, and the expectations of patients, regulators, and sponsors continue to shift.
“Expertise should guide innovation. Excellence should define our standards. Engagement should shape our relationships. Efficiency should make clinical research more practical. And ethics should remain non negotiable,” he says, laying out what amounts to a personal charter for the years ahead.
“Expertise should guide innovation. Effective work should define our standards. Engaged relationships should shape how we work with clients and partners. AEsthetics should reflect the care we bring to everything we deliver. And exposition, communicating clearly and honestly at every stage, should remain non-negotiable,” he says, laying out what amounts to a personal charter for the years ahead.
Ultimately, Marek measures success in terms that extend well beyond the number of studies CLINMARK has supported or the countries in which it has worked. He hopes the company’s lasting impact will be judged by its contribution to improving how clinical research itself is conducted.
“If we can help make clinical development more effective, more responsible and more patient focused, while bringing safe and valuable medical innovations closer to those who need them, then I believe we will have achieved something truly meaningful,” he says.
It is a fitting close to a conversation with a leader who has spent more than two decades proving that the most sophisticated solution in clinical research is rarely the most complicated one. For Marek, the future of the industry will belong to organizations that can combine scientific rigor with agility, technology with human judgment, and global ambition with practical execution, a balance he has spent his career learning to strike, one decision at a time.
